Radiolabelled Lu-Bispidine-Trastuzumab for Targeting Human Epidermal Growth Factor Receptor 2 Positive Cancers.

Radioimmunotherapy (RIT) is a promising alternative to conventional treatment options. Here, we present experimental work on the synthesis, radiochemistry, and in vivo performance of a lanthanoid-selective nonadentate bispidine ligand suitable for Lu ion complexation. The ligand (bisp,1) was derivatised with a photoactivatable aryl azide (ArN ) group as a bioconjugation handle for light-induced labelling of proteins.